Natacyn for Eyelid Inflammation

(CLEAR Trial)

Not yet recruiting at 4 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Brent Kramer
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to learn if Natacyn works to reduce or eliminate laboratory-confirmed fungal organisms in subjects with fungal-positive blepharitis identified in a previous study. asthma in adults. It will also learn more about the safety of Natacyn. The main questions it aims to answer are:

Does Natacyn reduce or eliminate fungal presence? Does Natacyn cause a reduction in eye irritation and itchiness? What medical problems do participants have when using Natacyn?

Participants will:

Apply Natacyn 4 times a day for 21 days Visit the clinic once every week for checkups and tests Keep a diary of the number of times they apply Natacyn over the 21-day period

Are You a Good Fit for This Trial?

This trial is for people with eyelid inflammation (blepharitis) caused by a fungal infection, confirmed in a previous study. Participants should be able to apply eye medication daily and attend weekly clinic visits.

Inclusion Criteria

I am a woman who can have children and will use effective birth control during the study.
I am 18 years old or older.
I have been diagnosed with blepharitis.
See 3 more

Exclusion Criteria

I currently have an eye infection or active keratitis.
Pregnancy or breastfeeding
Participation in another interventional ocular study
See 2 more

What Are the Treatments Tested in This Trial?

Trial Overview

The study tests if Natacyn, an antifungal eye drop used four times daily for 21 days, can reduce or eliminate fungus on the eyelids and improve symptoms like irritation and itchiness. Safety of the treatment will also be monitored.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: CLEAR - Clinical Lid Eradication of Antifungal-Responsive FUNGUS StudyExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Brent Kramer

Lead Sponsor